Marco Manoni

AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy.

Inalco SpA manufactures pharmaceutical active ingredients and food additives, and organic intermediates. It operates through the following business divisions: Pharmaceutical and Fine Chemicals which focuses on active ingredients and synthesis intermediates for pharmaceuticals, photochemicals, agrochemicals, and dyestuffs; Research Chemicals and Biochemicals which include organic reagents, biochemicals and immunochemicals, protected aminoacids and reagents for peptide chemistry, bioactive peptides, and phospholipids; and Specialty and Performance Chemicals such as modified alkyd resins, natural and synthetic tackifying resins, rosin derivatives, phenolic antioxidants and alkylphenols, and specialized monomers. The company is headquartered in Milan, Italy.

Primm SRL engages in the manufacturing, marketing and sale of biotech services. It offers poly and monoclonal antibodies, peptides, DNA synthesis, DNA sequencing, protein analysis, gene cloning, recombinant protein and pharmacological and toxicological services. The firm provides research and development activities which focuses on the design, synthesis, and pharmaceutical development of bioactive peptides for therapeutical applications. The company was founded by Sidoli Alessandro in 1990 and is based in Milan, Italy.